HEALTH TECHNOLOGY

Orb Health and Redox Collaborate to Increase Patient Access Care Management for Providers

Orb Health | July 05, 2021

Orb Health, a company that unlocks care capacity for health systems via enterprise patient access and virtual care management, has announced a collaboration with Redox, the industry-leading electronic health record (EHR) integration solution. Orb Health has enabled an EMR-connected, AI-based intelligence layer via this collaboration, which significantly enhances its inbound and proactive outbound service scalability and capabilities as they operate in the name of their provider clients.

 

The virtual contact center at Orb Health allows patients to interact with doctors and administrators who manage all aspects of their care, allowing for "one-touch resolution." This opens up scheduling space for brick-and-mortar physicians to respond to patients whose requirements need comprehensive in-person care. Furthermore, Orb Health's analytics layer delves into a patient's medical history and offers personalized recommendations on how to best meet that patient's needs. As a result, Orb Health customers have witnessed a 54% decline in chronic patient emergency department utilization.

 

About Redox

With a full-service integration platform for safely and effectively exchanging healthcare data, Redox accelerates the development and distribution of healthcare software solutions. Data can be transmitted across a growing network of 1,700+ healthcare delivery companies and 300 different software vendors with only one connection. Members of the Redox Network exchange around 20 million patient records every day, using a single data standard that is compatible with over 80 electronic health record systems. Redox exists to make healthcare data more useful and to improve every patient's experience.

 

About Orb Health

Orb Health is headquartered in Richardson, Texas, and collaborates with leading Accountable Care Organizations (ACOs), healthcare systems, Federally Qualified Health Centers (FQHCs), Community Health Centers (RHCs), and Payer organizations to improve patient outcomes and accelerate provider profitability. Our industry-leading Enterprise Virtual Care solution enables providers to increase care capacity for patient support, chronic care, and outbound clinical campaigns that deliver reimbursable, collaborative, patient-centric care coordination as an extension of the practice without the need for additional staff, applications, or office space. All stakeholders in the patient's outcome collaborate as a cohesive unit to achieve substantially better patient outcomes and satisfaction while improving reimbursements and reducing the healthcare cost curve.
 

Spotlight

Treatments for breast cancer have advanced dramatically in recent years. There are now many options for patients battling breast cancer to consider including clinical trials and immunotherapies.


Other News
DIGITAL HEALTHCARE

Revibe Technologies Announces Clinical Development Updates for its Investigational FokusRx Prescription Digital Therapy for the Treatment of ADHD

Revibe technologies | February 09, 2022

Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school aged children with attention deficit hyperactivity disorder (ADHD). FokusRx is an investigational SaMD (Software as a Medical Device) that has the potential to provide a new nonpharmacologic approach to treating attention, focus and hyperactivity deficits associated with ADHD, and other mental health conditions. ADHD is one of the most commonly diagnosed and increasingly prevalent mental health disorders in children and adolescents.Inthe United States, 6.1 million children aged 2-17 years have been diagnosed with ADHD. Approximately 50% of families stop using prescription drug treatments for ADHD within a year.Over 30% of parents refuse pharmacologic treatment for their children with ADHD. In this, single-arm multi-rater feasibility study, parents (n= 38) and teachers (n= 26) rated youth aged 8-12 years with a parent-reported diagnosis of ADHD. Youth were attending in-person classroom learning and not taking medication for their ADHD. The study included a number of outcome measures including the ADHD-RS-5 (Home and School versions), Conners 4 – short version, Weiss Functional Impairment Rating Scale-Parent Form (WFIRS-P), and the Academic Performance Rating Scale (APRS). To be included in the analyses, youth had to have worn the Revibe Connect wearable device to school Monday to Friday for a at least three days per week or a minimum of 15 days total for a period of four weeks. "We are pleased that the feasibility study has proven to be a successful exercise that de-risks our upcoming randomized sham-controlled pivotal trial. The moderate to large effect sizes observed and change scores that exceed standards for minimally important (clinically significant) differences, provide encouraging preliminary evidence supporting the efficacy of our intervention", says Dr.Lindsay Ayearst, Chief Scientific Officer of Revibe. Revibe's Scientific and Medical Advisory Board member, Dr.Margaret Weiss, Director of Clinical Research in Child Psychiatry at Cambridge Health Alliance, stated, "These results are consistent across both symptoms and functioning, and across informants.They would translate into clinically significant change. Most impressive is the demonstration of an effect on academic performance." "The data from the classroom feasibility study suggests FokusRx can effectively and safely improve ADHD symptoms and functioning in school-aged children. It is our intention that FokusRx will provide kids and parents another option to help them succeed and reach their full potential. We are excited to begin designing our pivotal trial planned for the fall." Joseph Koziak, Chief Executive Officer of Revibe About FokusRx FokusRx is an investigational SaMD designed to provide a new nonpharmacologic approach to treating symptoms and impairment associated with ADHD. The FokusRx software is embedded within a dedicated smart watch to act as a digital therapeutic wearable. About Revibe Technologies Revibe Technologies is passionate about leveraging technology to help children and adults with focus and attention problems overcome obstacles in order to succeed in life. Revibe Technologies hopes to be a resource for students, parents, teachers, schools, and clinicians.

Read More

DIGITAL HEALTHCARE

AMIH Announces Expansion of EPIQ MD’s Telehealth Platform and Services

Epiq MD | January 21, 2022

American International Holdings Corp., adiversified holding company that develops, acquires and operates technology-based health and wellness companies, today announced that its subsidiaryEPIQ MD, Inc.,has expanded the availability of its telehealth service offerings to thirteen (13) states across the United States. EPIQ MD, Inc., the convergence of primary care, mental health, preventative, and wellness programs through an online healthcare platform, announced its original launch and arrival in four statesback in September of 2021. Now with the introduction of their platform throughout the Southern U. S. border, EPIQ MD is directly on pace to achieve its goal of covering all 50 U. S. states by the year-end 2022 “This expansion of EPIQ MDs telehealth services and offerings across the Southern border of the United States further cements the sentiment that EPIQ MD has held since its official launch in September 2021”, comments Jacob Cohen, President and CEO of American International Holdings Corp. "Our vision is to be an essential service for millions of working families and individuals who currently don’t have any other viable options. Having access to a doctor or mental health professional 24/7/365 represents a crucial advancement in overall quality of life and we simply believe that the more eyes that are opened to EPIQ MD, the more we will be able to grow and expand.” EPIQ MD Director, Michael Ladner EPIQ MD is not simply bringing their expansive array of healthcare services to additional states, but are excited about their most recent introduction of Epiq PAWsand Epiq LUX. Epiq PAWs being EPIQ MD’s virtual care add-on tailored towards furry family members (a/k/a pets), and Epiq LUX being a wide-ranging discount program offering savings on a variety of ancillary medical services, including but not limited to, Laboratory Services, Dental, Vision, Chiropractic, Imaging and Diabetes/Home Medical Supplies. The Company believes that this current footprint represents a great mix of both urban and rural geographic locations, filled with demographics ripe for our primary care and mental health services. Seven of the states listed herein as our coverage area are also within the “top 10 states with the highest percentage of uninsured Americans”, according to the U.S. Central Bureau. While EPIQ MD envisions its platform spreading steadily throughout the United States as the year 2022 progresses, our strategy is to target the areas wherein we can make the biggest difference via our service offering. About EPIQ MD, Inc. EPIQ MD believes that everyone deserves to live an epic life. It is the convergence of primary medical and mental health care, preventative care and wellness programs - on one digital platform, in a single offering. Conceived as a digital telemedicine-based business from the start, its core mission is to bring these services and knowledge to the 80 million Americans who are uninsured or underinsured. Its telemedicine platform provides services such as primary care, medical advisory, ask a medical expert, mental health services, discounted diagnostic lab services, prescription discount program, nutritional counseling and much more. Today Epiq MD is active and operational in Alaska, Georgia, Illinois, Texas, Arizona, New Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah. About American International Holdings Corp. American International Holdings Corp. is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on bringing to market technologies and solutions that advance the quality of life for the global community.

Read More

MEDICAL DEVICES

Extremity Medical Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings and Zimmer, Inc.

Extremity Medical, LLC | April 07, 2022

Extremity Medical, LLC, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, announcedthat it filed a lawsuit against Nextremity Solutions, Inc.; Zimmer Biomet Holdings, Inc.; and Zimmer, Inc., alleging infringement of an Extremity Medical patent* for its intraosseous fixation platform arising from the marketing of the InCore® Lapidus System by these companies. The complaint was filed in the U.S. District Court for the District of Delaware. Extremity Medical has amassed an intellectual propertyportfolio that includes 49 patents in the U.S. and several foreign countries. The novel and patented technology of Extremity’s intraosseous fixation platform provides surgeons with a zero-profile solution for fusion and fixation of bones within the upper and lower extremities, with the ability to be implanted through minimal incisions. This technology is currently marketed globally by Extremity under the trade names IO FiX, IO FiX Plus, IO FiX 2.0, IO Freedom, CarpalFiX, ApeX and XMCP. “Extremity Medical has invested a tremendous amount of effort and resources in research and development to create innovative technology to improve the lives of patients and meet surgeons’ needs. Our intellectual property is a critical component in making such advancements possible and we are committed to protecting it,” Matthew Lyons, Extremity Medical Chief Executive Officer, Founder and Chairman of the Board About Extremity Medical, LLC Extremity Medical, was founded in 2008, and is a privately-held medical device company based in Parsippany, NJ. The company is known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation. The company is focused on developing solutions for challenging cases that promote better outcomes, especially in patients with poor bone quality.

Read More

HEALTH TECHNOLOGY

H2O.ai Showcases Healthcare and Life Sciences Leadership with Customer Successes, Breadth of AI Apps at HIMSS 2022

H2O.ai | March 14, 2022

H2O.ai, the AI Cloud leader, announced it has expanded its healthcare capabilities, now offering 40 AI applications across population health, precision medicine, public health and intelligent supply chain, supporting customers throughout the healthcare ecosystem including Bon Secours Mercy Health and Kaiser Permanente. The company will demonstrate its technologies at the healthcare industry’s flagship technology conference, HIMSS, in Booth No. 8141, March 15-17 at the Orange County Convention Center in Orlando. Healthcare and life sciences organizations have been stretched thin over the past few years and are actively looking for new technologies to streamline operations and improve patient outcomes across the private and public sectors. AI will empower physicians, hospital administrators, researchers and pharmaceutical companies with models and applications that produce more affordable, more accessible and more efficient healthcare. H2O.ai is at the forefront of this effort, helping organizations rapidly transform to improve health equity, access and care. For example, the Center for Digital Health Innovation (CDHI) at the University of California, San Francisco (UCSF) is collaborating with H2O.ai on the development and training of AI algorithms that automate the processing of the 1.4 million faxed patient referrals and other documents that UCSF’s health system receives annually. The algorithms identify, classify and prioritize document types. For referrals, the AI extracts key patient data, history and relevant health information that will assist staff and eliminate manual data entry and validation tasks. “AI in healthcare has the potential to dramatically improve the operational processes that can prevent patients from getting care quickly, at the right place, and from the right provider. Our work with H2O.ai for health document handling is just one aspect of the transformation in the ways patients access and receive care.” Alon Konchitsky, associate director for data science and machine learning at CDHI H2O.ai has developed 40 AI apps supporting various components of the healthcare ecosystem, including Population Health H2O.ai’s Covid-19 hospital occupancy simulator allows hospital administrators to track, predict and manage Covid-19-related hospital admissions by U.S. county. The company also has a pop-up predictor that allows for the quick identification of specific addresses in the U.S. that would be most suitable for temporary vaccination clinics, mobile testing centers, public education stands and more. H2O.ai’s customers - leading providers, payers and accountable care organizations (ACOs) - are developing and deploying AI models and apps around patient no shows, 30-day readmission predictors, risk stratification and omni-channel patient engagement NLP. Precision Medicine H2O.ai has developed a gene mutation app, a machine learning-powered patient risk assessment application that uses the Snowflake Data Cloud and the H2O AI Cloud to bring intelligent clinical decision support directly to clinicians. In another use case, H2O.ai’s gene expression tumor classification app uses gene expression information from patient biopsies to evaluate the risk of malignancy and understand how common the risk has been among past patients. “H2O AI Cloud, integrated with the Snowflake Data Cloud, is making it easier for health organizations to rapidly develop precision medicine solutions,” said Todd Crosslin, Global Head of Healthcare and Life Sciences at Snowflake. “The Gene mutation app is just the beginning of our health partnership and our ability to deliver improved care and patient outcomes.” Public Health The company’s Covid-19 forecasting application enables hospital staff, policymakers and others to predict the next wave of infection as well as potential case and death rates. H2O.ai also provides a vaccine sentiment tool that leverages natural language processing (NLP) to understand the sentiment around Covid-19 vaccines, and the company is currently working with leaders to address the risks and care associated with PASC (AKA Long COVID). Intelligent Supply Chain To provide intelligent supply chain support, H2O.ai’s route optimizer application helps health manufacturers best optimize transportation routes to ensure products arrive on time and to standard. H2O.ai also has developed an order and inventory management app to aid health manufacturers’ inefficient warehouse and inventory management decisions. Avoiding AI “Pilot-itis” Many health and life sciences organizations are struggling to implement AI projects that improve patient outcomes, reduce costs and more. Through its expertise and the H2O AI Cloud platform, H2O.ai is able to break companies out of the pilot cycle and successfully take them to AI maturity to deliver impactful results. In fact, H2O.ai has experienced an increase in healthcare customers moving from the pilot phase to full-blown production AI programs. “Artificial Intelligence and deep learning are not only driving the latest innovations in medicine but also are enabling healthcare organizations to connect fragmented data into a format that can be used to improve operational efficiency and provide more user-centric patient experiences,” said Sri Ambati, CEO and co-founder of H2O.ai. “From its use in drug discovery and forecasting the next COVID-19 variant to streamlining supply chain operations and reducing healthcare worker churn, AI will have a significant impact on democratizing health and improving patient outcomes.” About H2O.ai H2O.ai is the leading AI cloud company, on a mission to democratize AI for everyone. Customers use the H2O AI Cloud platform to rapidly solve complex business problems and accelerate the discovery of new ideas. H2O.ai is the trusted AI provider to more than 20,000 global organizations, including AT&T, Bon Secours Mercy Health, Capital One, Commonwealth Bank of Australia, GlaxoSmithKline, Hitachi, Kaiser Permanente, Procter & Gamble, PayPal, PwC, Reckitt, Unilever and Walgreens, over half of the Fortune 500 and one million data scientists. Goldman Sachs, NVIDIA and Wells Fargo are not only customers and partners, but strategic investors in the company. H2O.ai’s customers have honored the company with a Net Promoter Score (NPS) of 78— the highest in the industry based on breadth of technology and deep employee expertise. The world’s top 20 Kaggle Grandmasters (the community of best-in-the-world machine learning practitioners and data scientists) are employees of H2O.ai. A strong AI for Good ethos to make the world a better place and Responsible AI drive the company’s purpose. Please join our movement at H2O.ai.

Read More

Spotlight

Treatments for breast cancer have advanced dramatically in recent years. There are now many options for patients battling breast cancer to consider including clinical trials and immunotherapies.

Resources